deltatrials
Recruiting EARLY_PHASE1 INTERVENTIONAL 3-arm NCT04161248

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

A Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Sponsor: AbbVie

Conditions Lymphoma, B-Cell
Interventions Cisplatin Dexamethasone Gemcitabine Glofitamab Rituximab Injection Rituximab SC Tafasitamab Venetoclax
Updated 18 times since 2019 Last updated: Jan 29, 2026 Started: Sep 2, 2020 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04161248, this EARLY_PHASE1 trial focuses on Lymphoma, B-Cell and remains actively recruiting participants. Sponsored by AbbVie, it has been updated 18 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Dec 2019 – ~Oct 2020 · 10 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Feb 2023 · 12 months · monthly snapshot~Feb 2023 – ~Aug 2023 · 6 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Nov 2023 · 2 months · monthly snapshot~Nov 2023 – ~Mar 2024 · 4 months · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – ~Feb 2026 · 8 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

18 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting EARLY_PHASE1

  2. Jun 2025 — Feb 2026 [monthly]

    Recruiting EARLY_PHASE1

  3. Sep 2024 — Jun 2025 [monthly]

    Recruiting EARLY_PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting EARLY_PHASE1

  5. Apr 2024 — Jul 2024 [monthly]

    Recruiting EARLY_PHASE1

▶ Show 13 earlier versions

  1. Mar 2024 — Apr 2024 [monthly]

    Recruiting EARLY_PHASE1

  2. Nov 2023 — Mar 2024 [monthly]

    Recruiting EARLY_PHASE1

  3. Sep 2023 — Nov 2023 [monthly]

    Recruiting EARLY_PHASE1

  4. Aug 2023 — Sep 2023 [monthly]

    Recruiting EARLY_PHASE1

  5. Feb 2023 — Aug 2023 [monthly]

    Recruiting EARLY_PHASE1

  6. Feb 2022 — Feb 2023 [monthly]

    Recruiting EARLY_PHASE1

  7. Sep 2021 — Feb 2022 [monthly]

    Recruiting EARLY_PHASE1

  8. May 2021 — Sep 2021 [monthly]

    Recruiting EARLY_PHASE1

  9. Apr 2021 — May 2021 [monthly]

    Recruiting EARLY_PHASE1

  10. Feb 2021 — Apr 2021 [monthly]

    Recruiting EARLY_PHASE1

  11. Jan 2021 — Feb 2021 [monthly]

    Recruiting EARLY_PHASE1

  12. Oct 2020 — Jan 2021 [monthly]

    Recruiting EARLY_PHASE1

    Status: Not Yet Recruiting → Recruiting

  13. Dec 2019 — Oct 2020 [monthly]

    Not Yet Recruiting EARLY_PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
  • Canadian Cancer Trials Group
  • Incyte Corporation
  • Roche Pharma AG
Data source: Canadian Cancer Trials Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations